Placebo News and Research

RSS

St. John's wort not effective for treating ADHD

Children and teens with attention-deficit/hyperactivity disorder (ADHD) who were treated with the herb St. John's wort did not have any greater improvement in ADHD symptoms compared to those who received placebo, according to a study in the June 11 issue of JAMA, the Journal of the American Medical Association.

11 Jun 2008

Chinese red food colouring beats heart disease and cancer

According to a large study carried out in China, a red food colouring ingredient widely used in Chinese cooking protects against cancer and heart disease.

11 Jun 2008

Antibiotics can prevent wound complications of childbirth

A single dose of antibiotics can significantly aid healing of the severe tearing that occurs in vaginal tissues during many births, according to researchers at Lucile Packard Children's Hospital at Stanford, the Stanford University School of Medicine and Santa Clara Valley Medical Center. The study is the first to show that the simple treatment can prevent many of the short- and long-term repercussions of this relatively common complication of childbirth.

9 Jun 2008

Chinese red yeast rice reduces repeat heart attacks

A clinical study on patients who have suffered a heart attack found that a partially purified extract of Chinese red yeast rice, Xuezhikang (XZK), reduced the risk of repeat heart attacks by 45%, revascularization (bypass surgery/angioplasty), cardiovascular mortality and total mortality by one-third and cancer mortality by two-thirds.

9 Jun 2008

FDA grants pediatric exclusivity for UCB's Keppra

UCB has announced that the US Food and Drug Administration (FDA) has granted pediatric exclusivity for Keppra (levetiracetam). The decision was based on pediatric data submitted to the FDA following a written request in 2001.

8 Jun 2008

Drug used to treat alcohol dependence also works for pathological gamblers

Scientists in the U.S. have found that a drug commonly prescribed for the treatment of alcoholism and drug dependence, also works for pathological gamblers.

8 Jun 2008

Cancer patients report less fatigue while taking narcolepsy drug

A large, phase III clinical study showed the drug modafinil (Provigil) alleviated severe cancer-related fatigue for many patients, paving the way for the first reliable treatment for this debilitating and common side effect.

5 Jun 2008

Rochester probes drug therapy, parent training for kids with both autism, ADHD

A National Institutes of Health grant awarded earlier today will empower a team of University of Rochester investigators studying if a blend of drug and behavioral therapy can bring relief to the nearly one-fourth of children with autism who also live with symptoms of ADHD, or attention deficit hyperactivity disorder.

5 Jun 2008

ThromboGenics and BioInvent report positive results for anti-PlGF cancer therapeutic TB-403

ThromboGenics NV and co-development partner BioInvent International AB today reported that the results from the first Phase l study of novel anti-cancer agent TB-403 showed that it is safe and well tolerated, with pharmacokinetic properties enabling it to be developed for the treatment of cancer

3 Jun 2008

Probiotics provide hay fever hope

With the peak grass pollen season approaching, scientists can reveal that a daily dose of probiotic can change the immune status of people with hay fever.

2 Jun 2008

Monitoring blood flow helps improve prostate biopsies

Using a special ultrasound technique to spot areas of blood flow in the prostate gland may substantially reduce the number of unnecessary biopsies, according to a new study by urologists and radiologists at the Jefferson Prostate Diagnostic Center and the Kimmel Cancer Center at Jefferson in Philadelphia.

26 May 2008

Preservatives and food colours may be the culprits in ADHD

The suspicion that additives such as preservatives and artificial food colours can contribute to hyperactive behaviour in children has been around for years.

25 May 2008

Simple blood test could indicate higher risk for coronary events in women after post-menopausal hormone therapies

A research study has found that a simple blood test may indicate whether post-menopausal hormone therapies present an elevated risk of a heart attack.

22 May 2008

Reducing blockage fails to improve access to the bloodstream for kidney dialysis

Reducing early blockages in bloodstream access for kidney failure treatment does not increase the likelihood that the access will function adequately for long-term treatments, according to a study funded by the National Institutes of Health. Results were published May 14, 2008, in the Journal of the American Medical Association.

22 May 2008

Evidence mounts against DHEA use in treating cognitive decline

DHEA supplements are widely-available and touted as a preventive agent for many chronic diseases. A new study published in Journal of the American Geriatrics Society finds no evidence of a beneficial effect of DHEA supplements on cognitive function in healthy older adults. The researchers believe that based on their study, DHEA supplements should not be recommended for enhancement of cognitive function or well-being in the general population.

21 May 2008

New insights into the neural circuitry of trust

The brain centers triggered by a betrayal of trust have been identified by researchers, who found they could suppress such triggering and maintain trust by administering the brain chemical oxytocin. The researchers said their findings not only offer basic insights into the neural machinery underlying trust; the results may also help in understanding the neural basis of social disorders such as phobias and autism.

21 May 2008

New treatment option for idiopathic pulmonary fibrosis

Patients with idiopathic pulmonary fibrosis (IPF) may have a new treatment option, according to researchers in Japan.

20 May 2008

FDA approves Entereg (alvimopan) to restore bowel function

The U.S. Food and Drug Administration approved Entereg (alvimopan) today to accelerate the restoration of normal bowel function in patients 18 years and up who have undergone partial large or small bowel resection surgery. Entereg will be used in hospitalized patients who can receive no more than 15 doses.

20 May 2008

Radiofrequency ablation is an effective treatment for dysplasia in people with Barrett's esophagus

Interim results from a nationwide clinical trial led by a University of North Carolina at Chapel Hill researcher suggest that radiofrequency ablation is an effective treatment for dysplasia in people with Barrett's esophagus, a condition that can lead to deadly gastrointestinal cancer.

19 May 2008

Cancer drug shows promise as treatment for pulmonary hypertension

A drug developed to fight cancer is showing early promise as a treatment for pulmonary hypertension, researchers from the University of Chicago Medical Center report May 19 at the American Thoracic Society International Conference in Toronto, Canada.

19 May 2008